Partners taking aim at DED in American veterans
TearLab, MellingMedical reach an agreement to enhance early detection of dry eye disease in veterans.
Investigators identify an eye cancer culprit
A team of investigators have found that a molecular mechanism drives the progression of uveal melanoma, an often lethal eye cancer in adults.
Windows to the soul, eyes are key to meaningful conversation
Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.
Gilbert Family Foundation funds clinical study to understand vision loss from NF1 optic pathway glioma
Children’s Hospital of Philadelphia and Stanford University School of Medicine will lead the $5.4 million study ,with patient recruitment beginning in late 2021 or early 2022.
Companies announce eye care collaboration
AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
Analyzing macula dystrophy classifications
Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.
Apellis receives mixed results in two Phase 3 studies
Despite varied results, the company will submit a New Drug Application for pegcetacoplan for geographic atrophy to the FDA early next year.
Software plugin allows retina specialists to prepare, guide navigated laser treatment remotely
OD-OS’s teleguidance offering addresses the lack of experts and also benefits teaching in retina laser care.
Study finds lasting immunity and protection from COVID-19 by single-shot, room-temperature, stable vaccine
The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.
Pharmaceutical company files IND application with FDA for glaucoma candidate
TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.
Ida creating challenges for ophthalmologists, patients
Amid a surging COVID-19 pandemic, ophthalmologists in the path of Hurricane Ida are now dealing with the storm's impact.
American Academy of Ophthalmology, Research to Prevent Blindness announce grant recipients
According to the Academy and RPB, the grant recipients will use the IRIS Registry database to improve the diagnosis and treatment of eye disease.
Examining 10-year postop data on epi-off CXL for keratoconus, ectasia
Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.
Virtual training tackling leading cause of childhood blindness
Led by eye care nonprofit Orbis with support from Alcon, the training will build eye care professionals' skills to treat retinopathy of prematurity in Latin America
RVL Pharmaceuticals: Shifting toward ocular aesthetics
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Survey: Ophthalmology outpatient volume drops
According to McKinsey’s Hospital Insights Survey, hospital outpatient and procedural volumes were nearly 4 percent higher in July compared to 2019, but ophthalmology was down during the same period.
Study highlights favorable two-year outcomes of standalone use of surgical system on mild to moderate open-angle glaucoma
Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.
Alcon kicks off year-long partnership with Complexity Gaming
According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.
Company debuts automated sensorimotor exam system
RightEye Sensorimotor is a new technology designed to greatly improve patient care and increase optometry and ophthalmology practice revenue.
How new prior authorization policy affects cataract surgery
Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.
AAO requiring proof of COVID-19 vaccination for annual meeting attendees
The American Academy of Ophthalmology issued a guidance this week requiring all in-person attendees at its annual meeting Nov. 12-15 in New Orleans to show proof of COVID-19 vaccination.
German investigators grow brain cells with rudimentary ‘eyes’
Science fiction is quickly becoming science fact as a team of German scientists has developed a small, lab-grown brain cell cluster that developed fundamental eye structures.
Dry eye patients reveal misconceptions about condition in new survey
A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.
ASRS provides annual meeting health, safety update
The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Modernizing Medicine: New EHR innovations benefits eye care physicians
Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.
AAO applauds United Healthcare for policy clarification
The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.
Companies collaborating on Stargardt disease program
Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.
Biopharmaceutical firm taking next step in trials for intravitreal integrin antagonist
Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.
Impact of prior authorization for cataract surgery
Aurion Biotech: Treating endothelial disease with one donor
Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
2 Commerce Drive Cranbury, NJ 08512